Evidence map›Paper›PMID 32078443›Full record

ArticleHuman vaccines & immunotherapeutics2020

Retrospective study of the use of an influenza disease two-tiered classification system to characterize clinical severity in US children.

Amber Hsiao, Philip O Buck, Arnold Yee, John Hansen, Edwin M Lewis, Laurie L Aukes, Emad Yanni, Rafik Bekkat-Berkani, Anne Schuind, Nicola P Klein

Open access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Cytokine Storm Related to CD4Immune network · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Amber HsiaoKaiser Permanente Vaccine Study Center , Oakland, CA, USA.ORCID 0000-0003-2295-0886
Philip O BuckUS Health Outcomes and Epidemiology, Vaccines, GSK , Philadelphia, PA, USA.ORCID 0000-0002-3898-3669
Arnold YeeKaiser Permanente Vaccine Study Center , Oakland, CA, USA.
John HansenKaiser Permanente Vaccine Study Center , Oakland, CA, USA.
Edwin M LewisKaiser Permanente Vaccine Study Center , Oakland, CA, USA.
Laurie L AukesKaiser Permanente Vaccine Study Center , Oakland, CA, USA.
Emad YanniUS Health Outcomes and Epidemiology, Vaccines, GSK , Philadelphia, PA, USA.ORCID 0000-0001-9026-0735
Rafik Bekkat-BerkaniClinical R&D, Vaccines, GSK , Rockville, MD, USA.
Anne SchuindClinical R&D, Vaccines, GSK , Rockville, MD, USA.ORCID 0000-0003-3544-0682
Nicola P KleinKaiser Permanente Vaccine Study Center , Oakland, CA, USA.ORCID 0000-0003-1777-4814
Kaiser Permanente · USGlaxoSmithKline (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In children <5 years, influenza is associated with higher risk of serious disease and hospitalization when compared with other age groups. Influenza vaccination reduces the risk of influenza and vaccination may attenuate the severity of disease. Recent studies in Europe suggest that classifying influenza disease as mild versus moderate-to-severe (M-S) using a novel definition may be clinically significant. We retrospectively evaluated whether this M-S definition also characterized influenza severity in a cohort of US children. We included children <18 years at Kaiser Permanente Northern California with PCR-confirmed influenza during the 2013-2014 influenza season. We classified children as M-S if they had ≥1 symptom: fever >39°C, acute otitis media, lower respiratory tract infection (LRTI), or extra-pulmonary complications; otherwise, they were classified as mild. We used multivariable log-binomial models to assess whether M-S influenza disease was associated with increased healthcare utilization. Nearly half of the 1,105 influenza positive children were classified as M-S. Children 6-35 months had the highest proportion of M-S disease (35.1%), mostly due to LRTI (63.2%) and fever (44.6%). Children ≥6 months who had M-S disease were associated with a 1.6 to 2.8 times increased likelihood of having had an emergency department or any follow-up outpatient visits. Those who had M-S disease were associated with an increased likelihood of receiving antibiotics, with the highest likelihood in children 6-35 months (RR 9.0, 95% CI 4.1, 19.8). While more studies are needed, an influenza classification system may distinguish children with more clinically significant disease.

Indexed as

Influenza, HumanInfluenza VaccinesChildEuropeHospitalizationHumansInfantRetrospective StudiesVaccinationInfluenza Vaccinesdisease severityhealth outcomesInfluenzapediatric

Identifiers

PMID32078443
PMCPMC7482751
OpenAlexW3008720868

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.